Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

446
The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
446
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

442
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
442
Abnormal Proliferation02:23

Abnormal Proliferation

4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current advances in extended resections for non-small cell lung cancer-a narrative review.

Translational lung cancer research·2026
Same author

MiR-21 Is a Novel Diagnostic and Prognostic Circulating Biomarker in Pleural Mesothelioma.

Diagnostics (Basel, Switzerland)·2026
Same author

Autologous tumor-immune effusion cocultures enable ex vivo functional profiling of radiotherapy-immunotherapy combinations.

Journal of experimental & clinical cancer research : CR·2026
Same author

Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma.

Antioxidants (Basel, Switzerland)·2026
Same author

Surgical Results after Neoadjuvant Nivolumab and Platinum-based Chemotherapy for Resectable Lung Cancer. A Multicentre European Real Clinical Practice Analysis.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2025
Same author

Transbronchial Cryobiopsy under Simultaneous Confocal Laser Endomicroscopy Guidance for Peripheral Pulmonary Lesions: A Pilot Study.

Respiration; international review of thoracic diseases·2025

Related Experiment Video

Updated: Nov 30, 2025

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.2K

Malignant pleural mesothelioma: recent developments.

Katharina Sinn1, Berta Mosleh, M Alireza Hoda

  • 1Malignant Pleural Mesothelioma Program, Translational Thoracic Oncology, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Current Opinion in Oncology
|November 13, 2020
PubMed
Summary
This summary is machine-generated.

Recent advancements in malignant pleural mesothelioma (MPM) management include novel biomarkers and targeted therapies. While no major breakthroughs have occurred, ongoing research offers hope for improved patient outcomes in this aggressive cancer.

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.1K
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.5K

Related Experiment Videos

Last Updated: Nov 30, 2025

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.2K
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.1K
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.5K

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Medical Diagnostics

Background:

  • Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer with a poor prognosis.
  • Current management strategies are continuously evolving to improve patient outcomes.

Purpose of the Study:

  • To review recent developments in the diagnosis, staging, and treatment of MPM.
  • To highlight emerging biomarkers and therapeutic strategies for MPM management.

Main Methods:

  • Review of recent literature on MPM diagnosis, staging, biomarkers, and treatment.
  • Analysis of prognostic markers, imaging techniques, and novel therapeutic approaches.

Main Results:

  • Molecular markers (PDL-1, BRCA1, CDKN2A) and tumor volumetry are crucial for staging and prognosis.
  • Emerging blood-based biomarkers show potential but require clinical validation.
  • Promising treatment strategies include targeted therapies, immunotherapy, vaccination, and refined surgical/radiotherapy approaches.

Conclusions:

  • Despite progress, significant breakthroughs in MPM treatment are still needed.
  • Further research and clinical trials are essential to identify effective treatment candidates and improve patient survival.